New Short-Course radiation after prostate surgery shows promise

NCT ID NCT03570827

First seen Nov 01, 2025 · Last updated Jun 23, 2026 · Updated 38 times

Summary

This phase II trial tested a shorter, higher-dose radiation schedule (hypofractionation) in 53 men with high-risk prostate cancer after their prostate was removed. The goal was to see if this approach could control cancer with fewer side effects than standard radiation. Participants also received hormone therapy. The study is complete, and results focus on how long men stayed free of cancer recurrence.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PROSTATE ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Mayo Clinic in Arizona

    Scottsdale, Arizona, 85259, United States

  • Mayo Clinic in Rochester

    Rochester, Minnesota, 55905, United States

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

Hypofractionated radiation therapy and androgen suppression therapy

What this could lead to

If successful, this could offer a shorter, more convenient radiation schedule after prostate surgery with fewer side effects while still controlling cancer.

What could go wrong

This is a small, early-phase trial (53 people) with no comparison group, so results may not apply broadly. Side effects from radiation and hormone therapy are possible.

Conditions

The condition(s) this trial relates to.

prostate adenocarcinoma prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.